penicillamine has been researched along with Proteinuria in 125 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 9.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| "Alclofenac and D-penicillamine were compared under controlled, double-blind conditions in the treatment of 35 patients with active rheumatoid arthritis over a period of 26 weeks." | 9.04 | The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. ( Aylward, M; Holly, F; Maddock, J; Rees, P, 1975) |
| "To determine if a policy of continuing penicillamine therapy in successfully treated patients with rheumatoid arthritis in the presence of persistent proteinuria, was associated or not with resolution of this adverse effect, a computer record of patients receiving penicillamine for rheumatoid arthritis was searched for patients with persistent proteinuria and the case notes of these patients reviewed." | 7.68 | Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis. ( DeSilva, RN; Eastmond, CJ, 1992) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 7.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "In a 3-centre study involving 144 patients with rheumatoid arthritis (RA), a relationship between side effects from D-penicillamine and HLA antigens, allotypic markers of the IgG heavy chain (Gm) and allotypes of complement components Bf, C4A and C4B was sought." | 7.67 | Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. ( Hannah, MC; Major, GA; Mathews, JD; McCluskey, J; Muirden, KD; Property, DN; Stockman, A; Tait, BD; Zilko, PJ, 1986) |
| "We studied patients with rheumatoid arthritis who have been treated with aurothioglucose (Au) and subsequently with D-penicillamine (DP), and who developed drug-induced proteinuria, over a 10-year period." | 7.67 | The relationship between aurothioglucose- and D-penicillamine-induced proteinuria. ( Rasker, JJ; Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1984) |
| "During the period 1976-1983, 67 patients with rheumatoid arthritis attending the arthritis clinics at Groote Schuur Hospital and Princess Alice Orthopaedic Hospital, Cape Town, were treated with penicillamine." | 7.67 | Penicillamine therapy in rheumatoid arthritis. ( Grobbelaar, J; Meyers, OL, 1984) |
| "To assess therapeutic effect and toxicity of D-penicillamine in relation to HLA antigens, 111 consecutive patients with rheumatoid arthritis (RA) were followed for a period of 7-9 years." | 7.67 | Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. ( Ament, BJ; Feltkamp, BW; Moens, HJ; van der Korst, JK, 1987) |
| " D-penicillamine, a drug effective in the proliferative synovitis of rheumatoid arthritis, was evaluated in a rabbit model of hemarthroses-induced arthritis and in four hemophiliacs with chronic synovitis." | 7.67 | Treatment of hemophilic arthritis with D-penicillamine: a preliminary report. ( Corrigan, JJ; Damiano, ML; Gall, EP; Jeter, M; Kolba, KS; Meredith, K; Trombley, J, 1985) |
| "Twenty-six of 300 patients (9%) with rheumatoid arthritis (RA) developed penicillamine-induced proteinuria." | 7.67 | Penicillamine-induced proteinuria: risk factors. ( Dillon, AM; Schroeder, ML; Stein, HB, 1986) |
| " proteinuria, haematological abnormalities, stomatitis, diarrhoea and dermatitis) in rheumatoid arthritis (RA) to sodium aurothiomalate (gold) and to D-penicillamine (PA) were studied in 32 patients." | 7.67 | HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Bjelle, A; Dahlqvist, SR; Möller, E; Ström, H, 1985) |
| "To investigate the possible relation between certain HLA antigens and toxicity during treatment with sodium aurothiomalate of D-penicillamine, we studied 91 patients with rheumatoid arthritis." | 7.66 | HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Batchelor, JR; Gibson, TJ; Griffin, J; Panayi, GS; Welsh, KI; Wooley, PH, 1980) |
| "Adverse effects to D-penicillamine were studied prospectively over 3 years in 259 patients with rheumatoid arthritis." | 7.66 | Adverse effects of D-penicillamine in rheumatoid arthritis. ( Atkins, CJ; Offer, RC; Patterson, AC; Robinson, HS; Stein, HB; Teufel, A, 1980) |
| "Ninety patients with rheumatoid arthritis who had received courses of gold followed by penicillamine for their disease were evaluated to determine the predictiveness of a certain response or adverse reaction to gold for the same response or adverse reaction to penicillamine." | 7.66 | Sequential gold and penicillamine therapy in rheumatoid arthritis. ( Cassady, J; Halla, JT; Hardin, JG, 1982) |
| "The difficulties encountered in administering D-penicillamine to 40 patients with rheumatoid arthritis (RA) over a six to 24 month period are recorded." | 7.66 | Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. ( Barraclough, D; Kincaid-Smith, P; Macdonald, I; Muirden, KD; Richter, D; Stockman, A, 1979) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 7.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis." | 7.66 | Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis. ( Essigman, WK, 1982) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 7.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "By means of a case-control study we investigated the association between HLA phenotypes and the development of proteinuria after aurothioglucose or D-penicillamine treatment in patients with rheumatoid arthritis (RA)." | 7.66 | HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. ( de Rooij, DJ; Rasker, JJ; Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1983) |
| "Penicillamine has been successfully reintroduced and continued for a minimum of 13 months in 5 patients who developed proteinuria during the first course of the drug." | 7.66 | Resumption of treatment with penicillamine after proteinuria. ( Davison, AM; Hill, A; Hill, H, 1979) |
| "There is much individual variation in the response of rheumatoid arthritis (RA) to penicillamine, some patients deriving benefit from very small doses." | 7.66 | Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between a standard and a response-related flexible regimen. ( Brown, RM; Day, AT; Golding, JR; Hill, AG; Hill, HF; Lyle, WH, 1979) |
| "Twenty-five patients with rheumatoid arthritis treated with D-penicillamine were retrospectively reviewed for signs of drug intolerance." | 7.66 | The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy. ( Billingsley, LM; Stevens, MB, 1981) |
| "Fourteen patients who developed persistent proteinuria while on penicillamine for rheumatoid arthritis, were collected over a period of one year." | 7.65 | Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. ( Amer, B; Bacon, PA; Cumming, RH; Mackenzie, JC; Tribe, CR; Verrier-Jones, J, 1976) |
| "This report includes 31 patients who developed a perimembranous glomerulonephritis generally 7 months after the onset of the treatment of various illnesses with D-Penicillamine." | 7.65 | [Perimembranous glomerulonephritis after treatment with D-penicillamine. Report on 31 cases (author's transl)]. ( Bohle, A; Gärtner, HV; Hallauer, W; Hoppe-Seyler, G; Lüttgen, FM; Neild, GH; Schollmeyer, P, 1975) |
| "A 61-year-old man suffering from active generalized scleroderma developed pemphigus foliaceus after 9 months of D-penicillamine therapy, 900-1200 mg daily." | 7.65 | Penicillamine-induced pemphigus foliaceus. ( Kristensen, JK; Wadskov, S, 1977) |
| "Proteinuria is observed in 10% of the patients, often secondary to extramembranous glomerulopathy." | 5.30 | [Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D]. ( Bridoux, F; Ducq, P; Gheerbrant, JD; Kyndt, X; Makdassi, R; Reumaux, D; Vanhille, P, 1999) |
| "A retrospective study of penicillamine toxicity in 156 patients yielded a high incidence of toxic reaction (62%), necessitating discontinuation of the drug therapy in 36% of the patients." | 5.26 | Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis. ( Bernhard, GC; Goldman, AL; Halverson, PB; Kozin, F, 1978) |
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 5.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| "Alclofenac and D-penicillamine were compared under controlled, double-blind conditions in the treatment of 35 patients with active rheumatoid arthritis over a period of 26 weeks." | 5.04 | The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. ( Aylward, M; Holly, F; Maddock, J; Rees, P, 1975) |
| "To determine if a policy of continuing penicillamine therapy in successfully treated patients with rheumatoid arthritis in the presence of persistent proteinuria, was associated or not with resolution of this adverse effect, a computer record of patients receiving penicillamine for rheumatoid arthritis was searched for patients with persistent proteinuria and the case notes of these patients reviewed." | 3.68 | Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis. ( DeSilva, RN; Eastmond, CJ, 1992) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 3.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "To elucidate the natural course of gold and penicillamine nephropathy and to facilitate appropriate clinical management 54 patients with rheumatoid arthritis who developed proteinuria during treatment with intramuscular gold thiomalate (21) or oral D penicillamine (33) were studied in detail throughout the whole of their renal illnesses." | 3.67 | The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients. ( Hall, CL, 1989) |
| "To elucidate the natural course of the nephropathy associated with penicillamine and thereby facilitate its clinical management 33 patients with rheumatoid arthritis who developed proteinuria during treatment with oral penicillamine were studied in detail throughout their renal illness." | 3.67 | Natural course of penicillamine nephropathy: a long term study of 33 patients. ( Bacon, PA; Hall, CL; Harrison, PR; Jawad, S; Klouda, PT; MacIver, AG; MacKenzie, JC, 1988) |
| "Ninety-five rheumatoid arthritis patients treated with aurothiomalate and/or D-penicillamine have been studied for possible associations between HLA-A, -B, -DR antigens and various toxic reactions to the above drugs." | 3.67 | HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. ( Boki, K; Economidou, J; Fostiropoulos, G; Kappos-Rigatou, I; Pachoula-Papasteriades, C; Varla-Leftherioti, M, 1986) |
| "During the period 1976-1983, 67 patients with rheumatoid arthritis attending the arthritis clinics at Groote Schuur Hospital and Princess Alice Orthopaedic Hospital, Cape Town, were treated with penicillamine." | 3.67 | Penicillamine therapy in rheumatoid arthritis. ( Grobbelaar, J; Meyers, OL, 1984) |
| "To assess therapeutic effect and toxicity of D-penicillamine in relation to HLA antigens, 111 consecutive patients with rheumatoid arthritis (RA) were followed for a period of 7-9 years." | 3.67 | Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. ( Ament, BJ; Feltkamp, BW; Moens, HJ; van der Korst, JK, 1987) |
| "In a 3-centre study involving 144 patients with rheumatoid arthritis (RA), a relationship between side effects from D-penicillamine and HLA antigens, allotypic markers of the IgG heavy chain (Gm) and allotypes of complement components Bf, C4A and C4B was sought." | 3.67 | Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. ( Hannah, MC; Major, GA; Mathews, JD; McCluskey, J; Muirden, KD; Property, DN; Stockman, A; Tait, BD; Zilko, PJ, 1986) |
| "We studied patients with rheumatoid arthritis who have been treated with aurothioglucose (Au) and subsequently with D-penicillamine (DP), and who developed drug-induced proteinuria, over a 10-year period." | 3.67 | The relationship between aurothioglucose- and D-penicillamine-induced proteinuria. ( Rasker, JJ; Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1984) |
| "Twenty-six of 300 patients (9%) with rheumatoid arthritis (RA) developed penicillamine-induced proteinuria." | 3.67 | Penicillamine-induced proteinuria: risk factors. ( Dillon, AM; Schroeder, ML; Stein, HB, 1986) |
| "One hundred sixty-two consecutive patients with rheumatoid arthritis (RA) were studied for possible association between HLA antigens, particularly DR antigens, and disease characteristics and adverse reactions to gold or D-penicillamine treatment." | 3.67 | A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis. ( Dequeker, J; Van Wanghe, P; Verdickt, W, 1984) |
| " D-penicillamine, a drug effective in the proliferative synovitis of rheumatoid arthritis, was evaluated in a rabbit model of hemarthroses-induced arthritis and in four hemophiliacs with chronic synovitis." | 3.67 | Treatment of hemophilic arthritis with D-penicillamine: a preliminary report. ( Corrigan, JJ; Damiano, ML; Gall, EP; Jeter, M; Kolba, KS; Meredith, K; Trombley, J, 1985) |
| " proteinuria, haematological abnormalities, stomatitis, diarrhoea and dermatitis) in rheumatoid arthritis (RA) to sodium aurothiomalate (gold) and to D-penicillamine (PA) were studied in 32 patients." | 3.67 | HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Bjelle, A; Dahlqvist, SR; Möller, E; Ström, H, 1985) |
| "By means of a case-control study we investigated the association between HLA phenotypes and the development of proteinuria after aurothioglucose or D-penicillamine treatment in patients with rheumatoid arthritis (RA)." | 3.66 | HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. ( de Rooij, DJ; Rasker, JJ; Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1983) |
| "To investigate the possible relation between certain HLA antigens and toxicity during treatment with sodium aurothiomalate of D-penicillamine, we studied 91 patients with rheumatoid arthritis." | 3.66 | HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Batchelor, JR; Gibson, TJ; Griffin, J; Panayi, GS; Welsh, KI; Wooley, PH, 1980) |
| "The incidence of adverse reactions to D-penicillamine in 155 patients with rheumatoid arthritis was analysed and compared with their history of adverse reactions to gold." | 3.66 | Adverse reactions to D-penicillamine after gold toxicity. ( Dodd, MJ; Griffiths, ID; Thompson, M, 1980) |
| "Over a 5-year period 325 patients with rheumatoid arthritis received treatment with gold (162) or D-penicillamine (163)." | 3.66 | Proteinuria in rheumatoid arthritis--drug-induced or amyloid? ( Bourke, BE; Scott, JT; Woodrow, DF, 1981) |
| "Twenty-five patients with rheumatoid arthritis treated with D-penicillamine were retrospectively reviewed for signs of drug intolerance." | 3.66 | The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy. ( Billingsley, LM; Stevens, MB, 1981) |
| "Adverse effects to D-penicillamine were studied prospectively over 3 years in 259 patients with rheumatoid arthritis." | 3.66 | Adverse effects of D-penicillamine in rheumatoid arthritis. ( Atkins, CJ; Offer, RC; Patterson, AC; Robinson, HS; Stein, HB; Teufel, A, 1980) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 3.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "8 patients who developed proteinuria whilst receiving penicillamine for rheumatoid arthritis have been studied." | 3.66 | Penicillamine nephropathy. ( Brewer, DG; McGinty, F; Ross, JH, 1980) |
| "18 patients with Wilson's disease with and without proteinuria and 19 test persons without Wilson's disease were examined for a disturbance of the transformation on account of phythemagglutinin, streptolysin-O and several D-penicillamine preparations by means of the lymphocyte transformation test." | 3.66 | [Immunologic studies with the lymphocyte transformation test on the side effects of D-penicillamine therapy in Wilson's disease]. ( Berger, H; Storch, W, 1980) |
| " In 9 of these patients a slight (4 patients) or a strong proteinuria (5 patients) appeared during the therapy with D-penicillamine." | 3.66 | [immunohistologic findings of kidney biopsies in Wilson's disease]. ( Ditscherlein, G; Lange, E; Lössner, J; Storch, W, 1980) |
| " The administration of N-acetyl-DL-penicillamine 24 h after 63Ni injection increased significantly the urinary excretion of the metal and restored proteinuria during the next 24 h." | 3.66 | Pattern of urinary 63Ni excretion in rats. ( Behari, JR; Tandon, SK; Verma, HS, 1980) |
| "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis." | 3.66 | Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis. ( Essigman, WK, 1982) |
| "The difficulties encountered in administering D-penicillamine to 40 patients with rheumatoid arthritis (RA) over a six to 24 month period are recorded." | 3.66 | Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. ( Barraclough, D; Kincaid-Smith, P; Macdonald, I; Muirden, KD; Richter, D; Stockman, A, 1979) |
| "Characteristics of patients on penicillamine therapy for rheumatoid arthritis were correlated with the occurrence of different side-effects." | 3.66 | Factors affecting the development of penicillamine side-effects. ( Corke, CF; Huskisson, EC, 1978) |
| "Penicillamine has been successfully reintroduced and continued for a minimum of 13 months in 5 patients who developed proteinuria during the first course of the drug." | 3.66 | Resumption of treatment with penicillamine after proteinuria. ( Davison, AM; Hill, A; Hill, H, 1979) |
| "There is much individual variation in the response of rheumatoid arthritis (RA) to penicillamine, some patients deriving benefit from very small doses." | 3.66 | Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between a standard and a response-related flexible regimen. ( Brown, RM; Day, AT; Golding, JR; Hill, AG; Hill, HF; Lyle, WH, 1979) |
| "Ninety patients with rheumatoid arthritis who had received courses of gold followed by penicillamine for their disease were evaluated to determine the predictiveness of a certain response or adverse reaction to gold for the same response or adverse reaction to penicillamine." | 3.66 | Sequential gold and penicillamine therapy in rheumatoid arthritis. ( Cassady, J; Halla, JT; Hardin, JG, 1982) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 3.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine." | 3.65 | Immunopathology of penicillamine-induced glomerular disease. ( Dische, FE; Hamilton, EB; Parsons, V; Swinson, DR, 1976) |
| " Masugi nephritis, heterologous and autologous immune complex nephritis as well as D-penicillamine induced glomerulonephritis were studied in rabbits, guinea pigs and rats." | 3.65 | Molecular weight analysis of proteinuria in experimental glomerulopathies. ( Batsford, SR; Boesken, WH; Schmitz-Hübner, U; Schneider, G, 1976) |
| "Fourteen patients who developed persistent proteinuria while on penicillamine for rheumatoid arthritis, were collected over a period of one year." | 3.65 | Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. ( Amer, B; Bacon, PA; Cumming, RH; Mackenzie, JC; Tribe, CR; Verrier-Jones, J, 1976) |
| "This report includes 31 patients who developed a perimembranous glomerulonephritis generally 7 months after the onset of the treatment of various illnesses with D-Penicillamine." | 3.65 | [Perimembranous glomerulonephritis after treatment with D-penicillamine. Report on 31 cases (author's transl)]. ( Bohle, A; Gärtner, HV; Hallauer, W; Hoppe-Seyler, G; Lüttgen, FM; Neild, GH; Schollmeyer, P, 1975) |
| "A 61-year-old man suffering from active generalized scleroderma developed pemphigus foliaceus after 9 months of D-penicillamine therapy, 900-1200 mg daily." | 3.65 | Penicillamine-induced pemphigus foliaceus. ( Kristensen, JK; Wadskov, S, 1977) |
| "LMW proteinuria was elevated almost exclusively in the first 2 years after the start of treatment, indicating early tubular damage." | 2.68 | Proteinuria and other renal functions in Wilson's disease. ( Feist, D; Ruder, H; Schärer, K; Sözeri, E, 1997) |
| "We describe here 4 cases of minimal change disease following exposure to mercury-containing skin lightening cream for 2 - 6 months." | 1.39 | Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases. ( Chan, TY; Chu, KH; Fung, SK; Lee, W; Mak, YF; Tang, HL; Tong, KL, 2013) |
| "Proteinuria is observed in 10% of the patients, often secondary to extramembranous glomerulopathy." | 1.30 | [Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D]. ( Bridoux, F; Ducq, P; Gheerbrant, JD; Kyndt, X; Makdassi, R; Reumaux, D; Vanhille, P, 1999) |
| "There is no accepted or proven treatment for localized scleroderma." | 1.28 | D-penicillamine in the treatment of localized scleroderma. ( Falanga, V; Medsger, TA, 1990) |
| " Adverse effects occurred more frequently after rapid increases in dosage." | 1.27 | The toxicity of D-penicillamine in systemic sclerosis. ( Blair, S; Medsger, TA; Steen, VD, 1986) |
| "A retrospective study of penicillamine toxicity in 156 patients yielded a high incidence of toxic reaction (62%), necessitating discontinuation of the drug therapy in 36% of the patients." | 1.26 | Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis. ( Bernhard, GC; Goldman, AL; Halverson, PB; Kozin, F, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (88.80) | 18.7374 |
| 1990's | 11 (8.80) | 18.2507 |
| 2000's | 1 (0.80) | 29.6817 |
| 2010's | 1 (0.80) | 24.3611 |
| 2020's | 1 (0.80) | 2.80 |
| Authors | Studies |
|---|---|
| Borrego García, E | 1 |
| Hernández García, E | 1 |
| Caba Molina, M | 1 |
| Navas-Parejo Casado, AM | 1 |
| Tang, HL | 1 |
| Mak, YF | 1 |
| Chu, KH | 1 |
| Lee, W | 1 |
| Fung, SK | 1 |
| Chan, TY | 1 |
| Tong, KL | 1 |
| Zhuang, XH | 1 |
| Mo, Y | 1 |
| Jiang, XY | 1 |
| Chen, SM | 1 |
| Rosenberg, LE | 3 |
| Hayslett, JP | 3 |
| Panayi, GS | 3 |
| Huston, G | 1 |
| Shah, RR | 1 |
| Mitchell, SC | 1 |
| Idle, JR | 1 |
| Smith, RL | 1 |
| Waring, RH | 1 |
| Farr, M | 1 |
| Tunn, E | 1 |
| Crockson, AP | 1 |
| Bacon, PA | 3 |
| Halla, JT | 1 |
| Cassady, J | 1 |
| Hardin, JG | 1 |
| Kean, WF | 3 |
| Lock, CJ | 1 |
| Howard-Lock, HE | 1 |
| Buchanan, WW | 2 |
| Essigman, WK | 1 |
| Dequeker, J | 1 |
| Van Wanghe, P | 1 |
| Verdickt, W | 1 |
| Dumler, F | 1 |
| Speerstra, F | 2 |
| Reekers, P | 2 |
| van de Putte, LB | 2 |
| Vandenbroucke, JP | 2 |
| Rasker, JJ | 2 |
| de Rooij, DJ | 1 |
| Gärtner, HV | 4 |
| Anastassiades, TP | 2 |
| Dwosh, IL | 2 |
| Ford, PM | 3 |
| Kelly, WG | 1 |
| Dok, CM | 1 |
| Grobbelaar, J | 1 |
| Meyers, OL | 1 |
| Wooley, PH | 2 |
| Griffin, J | 2 |
| Batchelor, JR | 2 |
| Welsh, KI | 1 |
| Gibson, TJ | 2 |
| Dodd, MJ | 1 |
| Griffiths, ID | 1 |
| Thompson, M | 1 |
| Rickers, H | 1 |
| Urfe, P | 1 |
| Rasmussen, GG | 1 |
| Brøchner-Mortensen, J | 1 |
| Bourke, BE | 1 |
| Woodrow, DF | 1 |
| Scott, JT | 1 |
| Stein, HB | 3 |
| Ruedy, J | 1 |
| Atkins, CJ | 2 |
| Offer, RC | 2 |
| Welsh, K | 1 |
| Quigley, MR | 1 |
| Richfield, M | 1 |
| Krumlovsky, FA | 1 |
| Kanwar, YS | 1 |
| Carone, FA | 1 |
| Jarrett, MP | 1 |
| Caspi, D | 1 |
| Fishel, R | 1 |
| Varon, M | 1 |
| Yona, E | 1 |
| Baratz, M | 1 |
| Yaron, M | 1 |
| Billingsley, LM | 1 |
| Stevens, MB | 1 |
| Matthes, KJ | 1 |
| O'Brien, WM | 1 |
| Patterson, AC | 1 |
| Teufel, A | 1 |
| Robinson, HS | 1 |
| Kelly, HG | 1 |
| Metcalf, DL | 1 |
| Turner, RA | 1 |
| Agudelo, CA | 1 |
| Ross, JH | 1 |
| McGinty, F | 1 |
| Brewer, DG | 1 |
| Storch, W | 3 |
| Ditscherlein, G | 2 |
| Lange, E | 1 |
| Lössner, J | 2 |
| Berger, H | 1 |
| Verma, HS | 1 |
| Behari, JR | 1 |
| Tandon, SK | 1 |
| Castellví Suaña, JM | 1 |
| Xiol Quingles, X | 1 |
| Castellote Alonso, J | 1 |
| Guardiola Capón, J | 1 |
| Mathieson, PW | 1 |
| Peat, DS | 1 |
| Short, A | 1 |
| Watts, RA | 1 |
| Shibasaki, T | 1 |
| Matsumoto, H | 1 |
| Gomi, H | 1 |
| Ohno, I | 1 |
| Ishimoto, F | 1 |
| Sakai, O | 1 |
| Throssell, D | 1 |
| Brown, J | 1 |
| Furness, PN | 1 |
| Rutty, G | 1 |
| Walls, J | 1 |
| Harris, KP | 1 |
| Sözeri, E | 1 |
| Feist, D | 1 |
| Ruder, H | 1 |
| Schärer, K | 1 |
| Kyndt, X | 1 |
| Ducq, P | 1 |
| Bridoux, F | 1 |
| Reumaux, D | 1 |
| Makdassi, R | 1 |
| Gheerbrant, JD | 1 |
| Vanhille, P | 1 |
| Neild, GH | 3 |
| Bohle, A | 3 |
| Kristensen, JK | 1 |
| Wadskov, S | 1 |
| Palosuo, T | 1 |
| Kajander, A | 1 |
| von Essen, R | 1 |
| Milgrom, F | 1 |
| Lange, K | 1 |
| Zilko, PJ | 2 |
| Dawkins, RL | 1 |
| Cohen, ML | 1 |
| Stephens, AD | 3 |
| Purkiss, P | 1 |
| Watts, RW | 3 |
| Fenton, JC | 1 |
| Crawhall, JC | 2 |
| Boesken, WH | 1 |
| Batsford, SR | 2 |
| Schmitz-Hübner, U | 1 |
| Schneider, G | 1 |
| Muller, V | 1 |
| Krumhaar, I | 1 |
| Schneider, W | 1 |
| Hauftová, D | 1 |
| Ruchholtz, U | 1 |
| Maddock, J | 1 |
| Rees, P | 1 |
| Holly, F | 1 |
| Aylward, M | 1 |
| Somerville, W | 1 |
| Caughey, DE | 1 |
| Grigor, RR | 1 |
| Stockman, A | 2 |
| Richter, D | 1 |
| Barraclough, D | 1 |
| Muirden, KD | 2 |
| Macdonald, I | 1 |
| Kincaid-Smith, P | 1 |
| Corke, CF | 1 |
| Huskisson, EC | 3 |
| Hill, HF | 3 |
| Hill, H | 1 |
| Hill, A | 1 |
| Davison, AM | 1 |
| Hill, AG | 1 |
| Day, AT | 2 |
| Brown, RM | 1 |
| Golding, JR | 2 |
| Lyle, WH | 1 |
| Trnavský, K | 1 |
| Zbojanová, M | 1 |
| Halverson, PB | 1 |
| Kozin, F | 1 |
| Bernhard, GC | 1 |
| Goldman, AL | 1 |
| Cendrowski, W | 1 |
| Czlonkowska, A | 1 |
| Saxer, M | 1 |
| Oeding, A | 1 |
| Kaganas, G | 1 |
| Vogt, E | 1 |
| Seelig, HP | 1 |
| Seelig, R | 1 |
| Dische, FE | 2 |
| Swinson, DR | 2 |
| Hamilton, EB | 1 |
| Parsons, V | 1 |
| Rohrbach, R | 1 |
| Riede, UN | 1 |
| Sandritter, W | 1 |
| Kluthe, R | 1 |
| Brass, H | 1 |
| Genth, E | 1 |
| Hartl, PW | 1 |
| Bauerdick, H | 1 |
| Buss, H | 1 |
| Lapp, H | 1 |
| Heintz, R | 1 |
| Tribe, CR | 1 |
| Mackenzie, JC | 2 |
| Verrier-Jones, J | 1 |
| Cumming, RH | 1 |
| Amer, B | 1 |
| Perings, E | 1 |
| Junge, U | 1 |
| Otto, W | 1 |
| Pietruschka, WD | 1 |
| Beenken, O | 1 |
| Hallauer, W | 1 |
| Hoppe-Seyler, G | 1 |
| Lüttgen, FM | 1 |
| Schollmeyer, P | 1 |
| Hamilton, EE | 1 |
| Hrncír, Z | 1 |
| Tichý, M | 1 |
| Hickman, D | 1 |
| Risch, A | 1 |
| Camilleri, JP | 1 |
| Sim, E | 1 |
| Bluhm, RE | 1 |
| Breyer, JA | 1 |
| Bobbitt, RG | 1 |
| Welch, LW | 1 |
| Wood, AJ | 1 |
| Branch, RA | 1 |
| DeSilva, RN | 1 |
| Eastmond, CJ | 1 |
| Singal, DP | 1 |
| Falanga, V | 1 |
| Medsger, TA | 2 |
| Hall, CL | 3 |
| Tighe, R | 1 |
| Steen, VD | 1 |
| Blair, S | 1 |
| Domljan, Z | 1 |
| Borso, G | 1 |
| Marinković, M | 1 |
| Winter Fudurić, I | 1 |
| Pucar, I | 1 |
| Cikes, N | 1 |
| Jawad, S | 1 |
| Harrison, PR | 1 |
| Klouda, PT | 1 |
| MacIver, AG | 1 |
| Pachoula-Papasteriades, C | 1 |
| Boki, K | 1 |
| Varla-Leftherioti, M | 1 |
| Kappos-Rigatou, I | 1 |
| Fostiropoulos, G | 1 |
| Economidou, J | 1 |
| Dahlqvist, SR | 1 |
| Ström, H | 1 |
| Bjelle, A | 1 |
| Möller, E | 1 |
| Moens, HJ | 1 |
| Ament, BJ | 1 |
| Feltkamp, BW | 1 |
| van der Korst, JK | 1 |
| Major, GA | 1 |
| Tait, BD | 1 |
| Property, DN | 1 |
| Mathews, JD | 1 |
| Hannah, MC | 1 |
| McCluskey, J | 1 |
| Schroeder, ML | 1 |
| Dillon, AM | 1 |
| Corrigan, JJ | 1 |
| Kolba, KS | 1 |
| Gall, EP | 1 |
| Trombley, J | 1 |
| Damiano, ML | 1 |
| Meredith, K | 1 |
| Jeter, M | 1 |
| Felts, JH | 1 |
| King, JS | 1 |
| Boyce, WH | 1 |
| Wildhirt, E | 1 |
| Berry, H | 1 |
| Helmke, K | 1 |
| Velcovsky, H | 1 |
| Eichhorn, M | 1 |
| Federlin, K | 1 |
| Tausch, G | 1 |
| Bröll, H | 1 |
| Eberl, R | 1 |
| Wallnöfer, H | 1 |
| Hanusch, M | 1 |
| Amos, HE | 1 |
| Lee, PN | 1 |
| Butterworth, AD | 1 |
| Camus, JP | 1 |
| Crouzet, J | 1 |
| Guillien, P | 1 |
| Benichou, C | 1 |
| Lievre, JA | 1 |
| Gordon, MH | 1 |
| Ehrlich, GE | 1 |
| Lorenzen, I | 1 |
| Uitto, J | 1 |
| Ohlenschlaeger, K | 1 |
| Kobíková, M | 1 |
| Stáva, Z | 1 |
| Waskönig, FW | 1 |
| Meyer, W | 1 |
| Burry, HC | 1 |
| Hart, FD | 1 |
| Filipecki, S | 1 |
| Dabrowska, B | 1 |
| Szczepański, A | 1 |
| Glyda, J | 1 |
| Fulghum, DD | 1 |
| Katz, R | 1 |
| Elsas, LJ | 1 |
| Spargo, BH | 1 |
| Durant, JL | 1 |
| Bluestone, R | 1 |
| Grahame, R | 1 |
| Holloway, V | 1 |
| Holt, PJ | 1 |
| Revúsová, V | 1 |
| Zvara, V | 1 |
| Leu, ML | 1 |
| Strickland, GT | 1 |
| Gutman, RA | 1 |
| Wenzl, H | 1 |
| Kludas, M | 1 |
| Luke, RG | 2 |
| Briggs, JD | 1 |
| Fell, GS | 1 |
| Kennedy, AC | 1 |
| Bensch, KG | 1 |
| Kashgarian, M | 1 |
4 reviews available for penicillamine and Proteinuria
| Article | Year |
|---|---|
Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; | 1996 |
The management of cystinuria in 1976.
Topics: Cysteine; Humans; Penicillamine; Proteinuria | 1977 |
Canadian experience with penicillamine therapy for cystinuria.
Topics: Adolescent; Adult; Canada; Cysteine; Female; Humans; Male; Penicillamine; Proteinuria | 1977 |
[Effects and adverse effects of D-penicillamine].
Topics: Bone Marrow Diseases; Chronic Disease; Cystinuria; Erythropoiesis; Hepatitis; Hepatolenticular Degen | 1975 |
11 trials available for penicillamine and Proteinuria
| Article | Year |
|---|---|
Proteinuria and other renal functions in Wilson's disease.
Topics: Acetylglucosamine; Adolescent; Chelating Agents; Child; Child, Preschool; Female; Glomerular Filtrat | 1997 |
The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Proteins; Blood Sedimentation; C-Reactive Protein; Clinical Trials as T | 1975 |
Treatment of rheumatoid arthritis with penicillamine.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dru | 1977 |
Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study.
Topics: Adult; Ageusia; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Dyspepsia; Erythema; Fem | 1976 |
[D-penicillamine (Artamin) as basic therapeutic agent in the treatment of chronic rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Chronic Disease; Clinical Trials as Topic; | 1973 |
[Treatment of chronic hepatitis with immunosuppressive agents and D-penicillamine].
Topics: Agranulocytosis; Azathioprine; Chronic Disease; Clinical Trials as Topic; Drug Hypersensitivity; Fem | 1973 |
Penicillamine in rheumatoid disease: a long-term study.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Blood Sedimentation; Body Weight; Clinical Trials as Topic; | 1974 |
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin].
Topics: Adult; Aged; Antibody Specificity; Arthritis, Rheumatoid; Clinical Trials as Topic; Copper; Dyspepsi | 1974 |
Penicillamine for treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Copper; Drug Evaluation; Gastr | 1974 |
Absence of toxic or therapeutic interaction between penicillamine and previously administered gold in a trial of penicillamine in rheumatoid disease.
Topics: Clinical Trials as Topic; Drug Interactions; Gold; Humans; Penicillamine; Proteinuria; Rheumatic Dis | 1974 |
The treatment of cystinuria with N-acetyl-D-penicillamine, a comparison with the results of D-penicillamine treatment.
Topics: Acylation; Adolescent; Adult; Child; Cysteine; Cystinuria; Desensitization, Immunologic; Drug Hypers | 1971 |
110 other studies available for penicillamine and Proteinuria
| Article | Year |
|---|---|
Massive proteinuria for minimal change nephropathy secondary to treatment with D-penicilamine in a patient with Wilson's disease. Case report.
Topics: Hepatolenticular Degeneration; Humans; Male; Middle Aged; Nephrosis, Lipoid; Penicillamine; Proteinu | 2020 |
Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases.
Topics: Administration, Cutaneous; Adult; Biopsy; Chelating Agents; Female; Humans; Kidney; Mercury Compound | 2013 |
Analysis of renal impairment in children with Wilson's disease.
Topics: Acetylglucosaminidase; Acidosis, Renal Tubular; Adolescent; Ceruloplasmin; Chelating Agents; Child; | 2008 |
Nephrotoxic effects of penicillamine in cystinuria.
Topics: Adult; Cystinuria; Female; Humans; Male; Penicillamine; Proteinuria | 1967 |
Deficient sulphoxidation status and D-penicillamine toxicity.
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Proteinuria; Sulfoxides; Thrombocytopenia | 1983 |
The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Tolerance; Dyspepsia; Female; Humans; Male; | 1984 |
Sequential gold and penicillamine therapy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Eruptions; gamma-Globulins; Gold; HLA Antigens; HLA-B Antigens; H | 1982 |
Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Drug Eruptions; Drug Interactions; Dysgeusia; | 1982 |
Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Eruptions; Humans; Lupus Erythematosus, Systemic; Male; Myastheni | 1982 |
A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Cytotoxicity Tests, Immunologic; Dermatitis; Dimerca | 1984 |
Drug-induced glomerulopathy: a selective review.
Topics: Anti-Inflammatory Agents; Captopril; Child; Gold; Humans; Kidney Diseases; Mitomycin; Mitomycins; Pe | 1983 |
HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Female; Genes, MHC Class II; Gold; HLA Antigens; HLA-DR Anti | 1983 |
The relationship between aurothioglucose- and D-penicillamine-induced proteinuria.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Gold; Histocompatibility Antigens Class II; HLA-DR Antigens; | 1984 |
Membranous (peri-, epi-, extramembranous) glomerulonephritis. Prototype of an immune complex glomerulonephritis. A clinical morphological study.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Blood Pressure; Child; Child, Preschool; Diabetes Comp | 1980 |
Efficacy and toxicity of D-penicillamine for rheumatoid disease in the elderly.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Drug Eruptions; Female; Gastrointestinal Diseases; | 1982 |
HLA antigens and drug toxicity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Gold; Histocompatibility Antigens Class II; HLA Antigens; HLA-DR3 Antigen; Hu | 1984 |
Penicillamine therapy in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Hematuria; Humans; Middle Aged; Penicillamine; Proteinuria; Retr | 1984 |
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Histocompatibility Testing; HLA | 1980 |
Adverse reactions to D-penicillamine after gold toxicity.
Topics: Arthritis, Rheumatoid; Gold Sodium Thiomalate; Humans; Penicillamine; Proteinuria; Skin Diseases | 1980 |
The glomerular filtration rate during penicillamine therapy in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Chromium Radioisotopes; Creatinine; Edetic Acid; Female; Glomeru | 1980 |
Penicillamine nephropathy.
Topics: Drug Administration Schedule; Humans; Kidney Diseases; Penicillamine; Proteinuria | 1981 |
Proteinuria in rheumatoid arthritis--drug-induced or amyloid?
Topics: Adult; Aged; Amyloidosis; Arthritis, Rheumatoid; Gold Sodium Thiomalate; Humans; Kidney Diseases; Ki | 1981 |
Penicillamine compared to previous chrysotherapy in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Gold; Humans; Male; Middle Aged; Penicillami | 1983 |
HLA antigens in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Gold; HLA Antigens; Humans; Inflammation; Major Histocompatibility Complex; P | 1980 |
Concurrent naproxen- and penicillamine-induced renal disease in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Glomerulonephritis; Humans; Kidney Diseases; Naproxen; Nephrit | 1982 |
Multisystem presentation of eosinophilic fasciitis.
Topics: Adult; Ankle Joint; Azathioprine; Blood Sedimentation; Bone Marrow Examination; Elbow Joint; Eosinop | 1982 |
The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Gold; HLA Antigens; Humans; Kidney Diseases; Male; Middl | 1981 |
Nephrotic syndrome in a patient with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Female; Humans; Hyperlipoproteinemias; Kidney; Kidney Glomerulu | 1981 |
Drug-induced proteinuria.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney; Kidney Diseases; Kidney Tub | 1981 |
Toxicity of D-penicillamine in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Interactions; Gold; Humans; Kid | 1980 |
Adverse effects of D-penicillamine in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Gastrointestinal Disea | 1980 |
The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Child; Digestive System; Dose-R | 1980 |
Penicillamine in rheumatoid arthritis: a clinical guide.
Topics: Arthritis, Rheumatoid; Humans; Monitoring, Physiologic; Penicillamine; Proteinuria | 1980 |
Penicillamine nephropathy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biopsy; Female; Humans; Kidney; Kidney Diseases; Male; Middle Ag | 1980 |
[immunohistologic findings of kidney biopsies in Wilson's disease].
Topics: Biopsy; Complement C3; Hepatolenticular Degeneration; Humans; Immunoglobulin G; Kidney; Penicillamin | 1980 |
[Immunologic studies with the lymphocyte transformation test on the side effects of D-penicillamine therapy in Wilson's disease].
Topics: Drug Hypersensitivity; Hepatolenticular Degeneration; Humans; Lymphocyte Activation; Penicillamine; | 1980 |
Pattern of urinary 63Ni excretion in rats.
Topics: Animals; Female; Nickel; Penicillamine; Proteinuria; Radioisotopes; Rats | 1980 |
[Nephrotic syndrome secondary to d-penicillamine in a patient with Wilson's disease].
Topics: Adolescent; Child; Female; Hepatolenticular Degeneration; Humans; Kidney Diseases; Male; Penicillami | 1993 |
Effects of a hepato-protective agent and a hepato-secreting chelator on cadmium-induced nephrotoxicity in Syrian hamsters.
Topics: Acetylglucosaminidase; Animals; Body Weight; Cadmium Chloride; Cadmium Poisoning; Carcinogens; Chela | 1996 |
D-penicillamine reduces renal injury in the remnant model of chronic renal failure in the rat.
Topics: Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Kidney; Kidney Failure, Chronic; | 1997 |
[Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D].
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Female; Glomerulonephritis; Human | 1999 |
Letter: D-penicillamine-induced membranous glomerulonephritis.
Topics: Arthritis, Rheumatoid; Glomerulonephritis; Hepatitis; Humans; Penicillamine; Proteinuria | 1975 |
Editorial: D-penicillamine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Cell Count; Drug Eruptions; Humans; Penicillamine; Proteinuria; Thrombo | 1975 |
Penicillamine-induced pemphigus foliaceus.
Topics: Humans; Male; Middle Aged; Pemphigus; Penicillamine; Proteinuria | 1977 |
Precipitating autoantibody to a ubiquitous tissue antigen: association with rheumatoid arthritis treated with sodium aurothiomalate or d-penicillamine.
Topics: Adolescent; Adult; Aged; Animals; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Autoantibodies; | 1978 |
Nephropathy induced by D-penicillamine.
Topics: Animals; Chemical Phenomena; Chemistry; Complement C1; Cysteine; Fluorescent Antibody Technique; Hap | 1978 |
Penicillamine treatment of rheumatoid arthritis: relationship of proteinuria and autoantibodies to immune status.
Topics: Arthritis, Rheumatoid; Autoantibodies; Humans; Immunoglobulins; Penicillamine; Proteinuria | 1977 |
Low Dose D-penicillamine in cystinuria.
Topics: Adolescent; Adult; Cysteine; Female; Humans; Penicillamine; Proteinuria | 1977 |
Serum immunoglobulins in D-penicillamine-treated cystinurics.
Topics: Cysteine; Humans; Immunoglobulin G; Immunoglobulins; Penicillamine; Proteinuria | 1977 |
Molecular weight analysis of proteinuria in experimental glomerulopathies.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Glomerulo | 1976 |
[Glomerulopathy in rheumatic patients due to penicillamine].
Topics: Adult; Antigen-Antibody Complex; Arthritis, Rheumatoid; Female; Glomerulonephritis; Humans; Kidney; | 1976 |
[Adverse effects of penicillamine].
Topics: Adult; Drug Eruptions; Edema; Female; Humans; Male; Penicillamine; Proteinuria | 1978 |
[Serious side effects with D-penicillamine therapy for Wilson's disease].
Topics: Basement Membrane; Complement C3; Glomerulonephritis; Hepatolenticular Degeneration; Humans; Immune | 1979 |
Penicillamine induced membranous glomerulonephritis.
Topics: Adult; Aged; Basement Membrane; Female; Glomerulonephritis; Humans; Kidney Glomerulus; Male; Middle | 1979 |
Surveillance costs of gold and penicillamine.
Topics: Arthritis, Rheumatoid; Costs and Cost Analysis; Gold; Humans; Penicillamine; Proteinuria; Reagent Ki | 1979 |
Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Biopsy; Dose-Response Relationship, Drug; Female; Humans; | 1979 |
Factors affecting the development of penicillamine side-effects.
Topics: Agglutination Tests; Antibodies, Antinuclear; Arthritis, Rheumatoid; Humans; Immunoglobulins; Latex | 1978 |
Resumption of treatment with penicillamine after proteinuria.
Topics: Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Penicillamine; Proteinuria | 1979 |
Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between a standard and a response-related flexible regimen.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1979 |
[Undesirable effects of D-penicillamine in the therapy of rheumatoid arthritis].
Topics: Ageusia; Arthritis, Rheumatoid; Humans; Kidney Diseases; Myasthenia Gravis; Penicillamine; Proteinur | 1979 |
Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; H | 1978 |
[Clinical experiences with d-penicillamine in rheumatoid arthritis (author's transl)].
Topics: Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Nausea; Penicillamine; Proteinuria; Skin M | 1977 |
[Proteinuria and nephrotic syndrome in penicillamine therapy. Reversibility of immunopathologic findings in animal experiments].
Topics: Albumins; Animals; Antibodies; Antigens; Basement Membrane; Cell Nucleus; Complement C3; DNA; Female | 1977 |
Immunopathology of penicillamine-induced glomerular disease.
Topics: Arthritis, Rheumatoid; Biopsy, Needle; Female; Humans; Kidney; Kidney Glomerulus; Male; Middle Aged; | 1976 |
Effects of D-penicillamine administration to rats, induction of renal changes: preliminary communication.
Topics: Animals; Dose-Response Relationship, Drug; Glomerulonephritis; Immunoglobulin G; Kidney Glomerulus; | 1976 |
[Glomerulopathy due to D-penicillamine--clinical findings and renal biopsy].
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Glomerulonephritis; Hu | 1976 |
Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study.
Topics: Adult; Antigen-Antibody Complex; Arthritis, Rheumatoid; Female; Humans; Kidney; Kidney Diseases; Kid | 1976 |
Editorial: Penicillamine: more lessons from experience.
Topics: Arthritis, Rheumatoid; Blood Cell Count; Drug Hypersensitivity; Humans; Penicillamine; Proteinuria; | 1975 |
[Early recognition of adverse effects, especially of kidney lesions, in patients with progressive chronic polyarthritis under D-Penicillamine therapy].
Topics: Arthritis, Rheumatoid; Chronic Disease; Humans; Kidney Diseases; Penicillamine; Proteinuria; Time Fa | 1975 |
[Perimembranous glomerulonephritis after treatment with D-penicillamine. Report on 31 cases (author's transl)].
Topics: Adolescent; Adult; Aged; Basement Membrane; Female; Glomerulonephritis; Hematuria; Humans; Kidney Gl | 1975 |
Penicillamine nephropathy.
Topics: Humans; Kidney Diseases; Kidney Glomerulus; Penicillamine; Proteinuria | 1975 |
[Proteinuria in immunopathological diseases during long-term penicillamine therapy (author's transl)].
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Penicillamine; Proteinuria; Scleroderma, Systemi | 1976 |
Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants.
Topics: Adult; Aged; Alleles; Arylamine N-Acetyltransferase; Base Sequence; Cloning, Molecular; DNA; Gene Am | 1992 |
Elemental mercury vapour toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part II: Hyperchloraemia and genitourinary symptoms.
Topics: Adult; Chelation Therapy; Chlorides; Construction Materials; Humans; Male; Mercury Poisoning; Middle | 1992 |
Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Edema; Humans; Penicillamine; Proteinuria | 1992 |
Is there a need to reclassify adult rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Female; Genes; Genetic Predisposition to Disease; Gold; HLA-DQ Antigens; HLA- | 1990 |
D-penicillamine in the treatment of localized scleroderma.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Nephrotic Syndrome; Penicillamine; Proteinur | 1990 |
The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients.
Topics: Adult; Arthritis, Rheumatoid; Creatinine; Female; Gold; Humans; Kidney; Kidney Diseases; Male; Middl | 1989 |
The effect of continuing penicillamine and gold treatment on the course of penicillamine and gold nephropathy.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Creatinine; Female; Gold; Humans; Kidney; Kidney Diseases; Male | 1989 |
The toxicity of D-penicillamine in systemic sclerosis.
Topics: Arthritis, Rheumatoid; Digestive System Diseases; Dose-Response Relationship, Drug; Drug Eruptions; | 1986 |
Renal changes in patients with rheumatoid arthritis treated with sodium thiomalate and D-penicillamine.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Humans; Male; Middle | 1987 |
Natural course of penicillamine nephropathy: a long term study of 33 patients.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; HLA Antigens; Humans; Kidney; Kidney Disease | 1988 |
HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Susceptibility; Female; Gold Sodium Thiomala | 1986 |
HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diarrhea; Drug Eruptions; Female; Gold Sodium Thiomalate; Histoc | 1985 |
Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Follow-Up Studies; HLA Antigens; HLA- | 1987 |
Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine.
Topics: Arthritis, Rheumatoid; Disease Susceptibility; Genetic Markers; Histocompatibility Antigens Class II | 1986 |
Penicillamine-induced proteinuria: risk factors.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Susceptibility; Female; Histocompatibility Antigens Clas | 1986 |
Treatment of hemophilic arthritis with D-penicillamine: a preliminary report.
Topics: Animals; Arthritis; Hemarthrosis; Hemophilia A; Humans; Inflammation; Penicillamine; Platelet Aggreg | 1985 |
Nephrotic syndrome after treatment with D-penicillamine.
Topics: Adult; Creatinine; Cystinuria; Female; Hepatolenticular Degeneration; Humans; Nephrotic Syndrome; Pe | 1968 |
[Penicillamine therapy of chronic liver diseases].
Topics: Azathioprine; Chronic Disease; Drug Hypersensitivity; Female; Glucocorticoids; Hepatitis; Humans; Li | 1974 |
Experience with penicillamine and azathioprine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Humans; Penicillamine; Proteinuria | 1974 |
Selection of patients with rheumatoid arthritis to be treated with penicillamine, and their management.
Topics: Administration, Oral; Arthritis, Rheumatoid; Blood Platelet Disorders; Feeding and Eating Disorders; | 1974 |
[Antinuclear factors during D-penicillamine therapy].
Topics: Antibodies, Antinuclear; Humans; Penicillamine; Proteinuria | 1974 |
Diagnosis of allergic drug reaction.
Topics: Antibodies, Antinuclear; Antibody Formation; Antigen-Antibody Complex; Coombs Test; Dextrans; Drug H | 1973 |
D-penicillamine in progressive scleroderma.
Topics: Adult; Aged; Biopsy; Blood Proteins; Blood Sedimentation; Collagen; Female; Hemoglobins; Humans; Hyd | 1972 |
[Penicillamine in the treatment of scleroderma].
Topics: Adult; Drug Evaluation; Female; Humans; Male; Middle Aged; Penicillamine; Proteinuria; Scleroderma, | 1973 |
[The basal therapy of rheumatoid arthritis with d-penicillamine (author's transl)].
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Proteinuria; Thrombocytopenia; Time Factors | 1973 |
Drug-induced nephropathies.
Topics: Animals; Arthritis, Rheumatoid; Aspirin; Colic; Complement System Proteins; Glomerular Filtration Ra | 1973 |
Penicillamine in the treatment of rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Gangrene; Humans; Middle Aged; Nausea; Penicillami | 1972 |
[Marked proteinuria in the course of penicillamine treatment of progressive systemic sclerosis].
Topics: Humans; Middle Aged; Penicillamine; Proteinuria; Scleroderma, Systemic | 1971 |
Penicillamine for scleroderma.
Topics: Animals; Drug Hypersensitivity; Feeding and Eating Disorders; Humans; Joint Diseases; Leukopenia; Pe | 1968 |
Wilson's disease with reversible renal tubular dysfunction. Correlation with proximal tubular ultrastructure.
Topics: Acute Kidney Injury; Adolescent; Antibodies, Antinuclear; Biopsy; Copper; Creatinine; Female; Glomer | 1971 |
Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment.
Topics: Adult; Aged; Elasticity; Female; Humans; Male; Middle Aged; Penicillamine; Proteinuria; Scleroderma, | 1970 |
[Problems in the therapy of cystine urolithiasis using penicillamine].
Topics: Adolescent; Cystine; Female; Humans; Male; Penicillamine; Proteinuria; Urinary Calculi | 1970 |
Renal function in Wilson's disease: response to penicillamine therapy.
Topics: Adolescent; Adult; Aminohippuric Acids; Ammonium Chloride; Calcium; Dehydration; Female; Follow-Up S | 1970 |
[Therapeutic problems during D-penicillamine treatment of patients with cystine calculi].
Topics: Adolescent; Adult; Albuminuria; Copper; Cystine; Cystinuria; Female; Humans; Kidney Calculi; Penicil | 1970 |
Proteinuria associated with D-penicillamine therapy of cystinuria.
Topics: Adult; Cystinuria; Electrophoresis; Female; Humans; Male; Middle Aged; Penicillamine; Proteinuria | 1968 |
Focal glomerulitis due to penicillamine.
Topics: Adult; Biopsy; Cystinuria; Drug Hypersensitivity; Female; Glomerulonephritis; Humans; Kidney Glomeru | 1968 |
Proteinuria during penicillamine therapy for cystinuria.
Topics: Adult; Cystinuria; Female; Humans; Male; Middle Aged; Penicillamine; Proteinuria | 1968 |
Some complications observed in the treatment of cystinuria with D-penicillamine and N-acetyl-D-penicillamine.
Topics: Adolescent; Adult; Child; Cystinuria; Drug Hypersensitivity; Female; Humans; Male; Penicillamine; Pr | 1968 |